首页 | 本学科首页   官方微博 | 高级检索  
检索        

550例局限期小细胞肺癌放化疗达缓解者预防性脑照射后脑转移风险评估
引用本文:陈梦圆,金佳男,季永领,胡晓,陈明.550例局限期小细胞肺癌放化疗达缓解者预防性脑照射后脑转移风险评估[J].中华放射肿瘤学杂志,2022,31(2):138-142.
作者姓名:陈梦圆  金佳男  季永领  胡晓  陈明
作者单位:中国科学院基础医学与肿瘤研究所 中国科学院大学附属肿瘤医院 浙江省肿瘤医院放疗科,杭州 310022
基金项目:浙江省卫生医药科技项目(2022KY618);国家卫生计生委科学研究基金-浙江省医药卫生重大科技计划(省部共建计划)项目(WKJ-ZJ-1701)。
摘    要:目的:评价影响放化疗后达完全缓解、部分缓解(CR/PR)的局限期小细胞肺癌(SCLC)患者预防性脑照射(PCI)后脑转移(BM)风险、预后因素。方法:收集2002—2017年间在浙江省肿瘤医院治疗疗效达CR/PR且经PCI治疗的550例局限期SCLC患者的基本资料,回顾分析PCI后BM风险因素及预后。采用 ...

关 键 词:癌,小细胞肺/放化疗法  预防性脑照射  脑转移  预后
收稿时间:2021-08-09

Risk assessment of brain metastasis after prophylactic cranial irradiation for 550 limited stage small cell lung cancer patients with remission after radiochemotherapy
Chen Mengyuan,Jin Jianan,Ji Yongling,Hu Xiao,Chen Ming.Risk assessment of brain metastasis after prophylactic cranial irradiation for 550 limited stage small cell lung cancer patients with remission after radiochemotherapy[J].Chinese Journal of Radiation Oncology,2022,31(2):138-142.
Authors:Chen Mengyuan  Jin Jianan  Ji Yongling  Hu Xiao  Chen Ming
Institution:Department of Radiation Oncology, Institute of Basic Medicine and Cancer of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China
Abstract:Objective To evaluate the risk and prognostic factors of brain metastasis(BM)after prophylactic cranial irradiation(PCI)in limited stage small cell lung cancer(LS-SCLC)patients with complete and partial remission(CR/PR)after radiochemotherapy.Methods Baseline data of 550 patients with LS-SCLC who obtained CR/PR after chemoradiotherapy and received PCI in Zhejiang Cancer Hospital between 2002 and 2017 were collected.The risk of BM and clinical prognosis were retrospectively analyzed.The survival analysis was performed by Kaplan-Meier method.Multivariate prognostic analysis was conducted byCox models.Results The overall BM rate after PCI was 15.6%(86/550),with 9%(4/43),13%(7/52),and 16.5%(75/455)for stageⅠ,Ⅱ and Ⅲ patients,respectively.The median overall survival(OS)for the entire cohort was 27.9 months,and the 5-year OS rate was 31.0%.The OS was 24.9 and 30.2 months for patients with or without BM,and the 5-year OS rates were 8.9% and 36.1%(P<0.001).BM was an independent factor of OS(P<0.001).Clinical staging remained the influencing factor of OS and BM-free survival(P<0.001,P=0.027).Having tumors of≥5cm in diameter significantly increased the risk of BM(P=0.034)rather than the OS(P=0.182).The median OS of patients aged<60 years was significantly longer than those aged≥60 years(34.9 months vs.24.6 months,P=0.001).The median OS of patients irradiated with 2 times/d was 29.8 months,significantly longer than 24.5 months of those irradiated with 1 time/d(P=0.013).Age,sex,radiotherapy fraction and efficacy of radiochemotherapy(CR/PR)were not associated with the incidence rate of BM(all P>0.05).Conclusions SCLC patients with tumors of≥5cm in diameter may have a higher risk of developing BM after PCI.Patients aged<60 years achieve better OS compared with their counterparts aged≥60 years.
Keywords:Carcinoma  small cell lung/radiochemotherapy  Prophylactic cranial irradiation  Brain metastasis  Prognosis
本文献已被 维普 等数据库收录!
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号